184 related articles for article (PubMed ID: 33358743)
1. Overexpression of CD200 and CD123 is a major influential factor in the clinical course of pediatric acute myeloid leukemia.
Kandeel EZ; Madney Y; Eldin DN; Shafik NF
Exp Mol Pathol; 2021 Feb; 118():104597. PubMed ID: 33358743
[TBL] [Abstract][Full Text] [Related]
2. Tracing Leukemia Stem Cells and Their Influence on Clinical Course of Adult Acute Myeloid Leukemia.
Kandeel EZ; El Sharkawy N; Hanafi M; Samra M; Kamel A
Clin Lymphoma Myeloma Leuk; 2020 Jun; 20(6):383-393. PubMed ID: 32201129
[TBL] [Abstract][Full Text] [Related]
3. A Real-world Perspective of CD123 Expression in Acute Leukemia as Promising Biomarker to Predict Treatment Outcome in B-ALL and AML.
Das N; Gupta R; Gupta SK; Bakhshi S; Malhotra A; Rai S; Singh S; Prajapati VK; Sahoo RK; Gogia A; Sharma A; Kumar L
Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e673-e684. PubMed ID: 32561191
[TBL] [Abstract][Full Text] [Related]
4. Expression of CD90, CD96, CD117, and CD123 on different hematopoietic cell populations from pediatric patients with acute myeloid leukemia.
Chávez-González A; Dorantes-Acosta E; Moreno-Lorenzana D; Alvarado-Moreno A; Arriaga-Pizano L; Mayani H
Arch Med Res; 2014 May; 45(4):343-50. PubMed ID: 24751333
[TBL] [Abstract][Full Text] [Related]
5. Immunoprofiling of leukemic stem cells CD34+/CD38-/CD123+ delineate FLT3/ITD-positive clones.
Al-Mawali A; Gillis D; Lewis I
J Hematol Oncol; 2016 Jul; 9(1):61. PubMed ID: 27465508
[TBL] [Abstract][Full Text] [Related]
6. Effect of Compound Zhebei Granule () combined with chemotherapy on surface markers of leukemia stem cell in patients with acute myeloid leukemia.
Wang J; Lai ZL; Chen XY; Li DY; Zhang YY; Ma W; Chu YT; Shi FQ; Yang L; Hou L
Chin J Integr Med; 2016 Jun; 22(6):438-44. PubMed ID: 26666761
[TBL] [Abstract][Full Text] [Related]
7. CD34+CD38-CD123+ Cells Are Present in Virtually All Acute Myeloid Leukaemia Blasts: A Promising Single Unique Phenotype for Minimal Residual Disease Detection.
Al-Mawali A; Pinto AD; Al-Zadjali S
Acta Haematol; 2017; 138(3):175-181. PubMed ID: 29065396
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-3 receptor α chain (CD123) is preferentially expressed in immature T-ALL and may not associate with outcomes of chemotherapy.
Du W; Li J; Liu W; He Y; Yao J; Liu Y; Lin J; Zheng J
Tumour Biol; 2016 Mar; 37(3):3817-21. PubMed ID: 26474588
[TBL] [Abstract][Full Text] [Related]
9. [Expression and Clinical Significance of Leukemia Stem Cell Antigen in Acute Myeloid Leukemia].
Yao DD; Han BQ; Han YF; Zhang YQ; Jin YL; Dai HB
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Dec; 26(6):1583-1588. PubMed ID: 30501688
[TBL] [Abstract][Full Text] [Related]
10. Impact of Leukemia Stem Cells Phenotype Expression on Response to Induction Therapy in Acute Myeloid Leukemia Patients.
Almohsen F; Al-Mudallal SS
Cardiovasc Hematol Disord Drug Targets; 2020; 20(2):145-151. PubMed ID: 31438833
[TBL] [Abstract][Full Text] [Related]
11. hMICL and CD123 in combination with a CD45/CD34/CD117 backbone - a universal marker combination for the detection of minimal residual disease in acute myeloid leukaemia.
Roug AS; Larsen HØ; Nederby L; Just T; Brown G; Nyvold CG; Ommen HB; Hokland P
Br J Haematol; 2014 Jan; 164(2):212-22. PubMed ID: 24152218
[TBL] [Abstract][Full Text] [Related]
12. Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid Leukemia.
Han L; Jorgensen JL; Brooks C; Shi C; Zhang Q; Nogueras González GM; Cavazos A; Pan R; Mu H; Wang SA; Zhou J; Ai-Atrash G; Ciurea SO; Rettig M; DiPersio JF; Cortes J; Huang X; Kantarjian HM; Andreeff M; Ravandi F; Konopleva M
Clin Cancer Res; 2017 Jul; 23(13):3385-3395. PubMed ID: 28096272
[No Abstract] [Full Text] [Related]
13. Expression of putative leukemia stem cell targets in genetically-defined acute myeloid leukemia subtypes.
Yanagisawa B; Perkins B; Karantanos T; Levis M; Ghiaur G; Smith BD; Jones RJ
Leuk Res; 2020 Dec; 99():106477. PubMed ID: 33220589
[TBL] [Abstract][Full Text] [Related]
14. [Changes of Leukemia Stem Cells in Acute Myeloid Leukemia before and after Treatment].
Lv JT; Yang ZG; Guang YH; Lin ZS; Xiao XX; Liu D; Shi M; Wang WS
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Jun; 26(3):658-664. PubMed ID: 29950200
[TBL] [Abstract][Full Text] [Related]
15. Impact of Concomitant Aberrant CD200 and BCL2 Overexpression on Outcome of Acute Myeloid Leukemia: A Cohort Study from a Single Center.
Tiribelli M; Michelutti A; Cavallin M; Di Giusto S; Fanin R; Damiani D
Turk J Haematol; 2021 Jun; 38(2):119-125. PubMed ID: 33596632
[TBL] [Abstract][Full Text] [Related]
16. Immunophenotypic Characterization of Cytogenetic Subgroups in Egyptian Pediatric Patients With B-Cell Acute Lymphoblastic Leukemia.
Adnan Awad S; Kamel MM; Ayoub MA; Kamel AM; Elnoshokaty EH; El Hifnawi N
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S19-S24.e1. PubMed ID: 27521317
[TBL] [Abstract][Full Text] [Related]
17. Universal monitoring of minimal residual disease in acute myeloid leukemia.
Coustan-Smith E; Song G; Shurtleff S; Yeoh AE; Chng WJ; Chen SP; Rubnitz JE; Pui CH; Downing JR; Campana D
JCI Insight; 2018 May; 3(9):. PubMed ID: 29720577
[TBL] [Abstract][Full Text] [Related]
18. [Immunophenotyping of leukemic stem cells and chromosome karyotype characteristics in Uyghur leukemia pediatric patients].
Hailiqiguli N; Yan M
Zhonghua Zhong Liu Za Zhi; 2013 Jul; 35(7):501-4. PubMed ID: 24257300
[TBL] [Abstract][Full Text] [Related]
19. Up-regulation of regulatory T cells, CD200 and TIM3 expression in cytogenetically normal acute myeloid leukemia.
Zahran AM; Mohammed Saleh MF; Sayed MM; Rayan A; Ali AM; Hetta HF
Cancer Biomark; 2018; 22(3):587-595. PubMed ID: 29843224
[TBL] [Abstract][Full Text] [Related]
20. Clinical Significance of CD200 and CD56 Expression in Patients with Acute Myeloid Leukemia.
Aref S; Abousamra N; El-Helaly E; Mabed M
Asian Pac J Cancer Prev; 2020 Mar; 21(3):743-748. PubMed ID: 32212802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
